Molecular docking analysis revealed lower binding energies of TB-2 with SRC, MAPK1, and KDR, and the significant role of these targets in cerebral ischemia treatment has been documented in previous literature (Mao et al., 2015; Liu et al., 2021; Chen et al., 2019). The gene discussed is MAPK1; the disease is Cerebral ischemia.